Biogen Inc. (NASDAQ:BIIB) went up by 2.93% from its latest closing price compared to the recent 1-year high of $468.55. The company’s stock price has collected 51.08% of gains in the last five trading sessions. The Wall Street Journal reported on 06/08/21 that FDA Approval of New Alzheimer’s Drug May Boost Prospects of Other Treatments
Is It Worth Investing in Biogen Inc. (NASDAQ :BIIB) Right Now?
Biogen Inc. (NASDAQ:BIIB) scored a price-to-earnings ratio above its average ratio, recording 21.35 x from its present earnings ratio. Plus, the 36-month beta value for BIIB is at 0.42. Opinions of the stock are interesting as 12 analysts out of 33 who provided ratings for Biogen Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 20 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $383.27, which is -$119.07 below the current price. BIIB currently public float of 149.58M and currently shorts hold a 2.03% ratio of that float. Today, the average trading volume of BIIB was 1.55M shares.
BIIB’s Market Performance
BIIB stocks went up by 51.08% for the week, with a monthly jump of 47.65% and a quarterly performance of 54.96%, while its annual performance rate touched 35.08%. The volatility ratio for the week stands at 17.22% while the volatility levels for the past 30 days are set at 6.01% for Biogen Inc.. The simple moving average for the period of the last 20 days is 41.09% for BIIB stocks with a simple moving average of 51.37% for the last 200 days.
Analysts’ Opinion of BIIB
Robert W. Baird, on the other hand, stated in their research note that they expect to see BIIB reach a price target of $382, previously predicting the price at $216. The rating they have provided for BIIB stocks is “Neutral” according to the report published on June 08th, 2021.
Citigroup gave a rating of “Neutral” to BIIB, setting the target price at $440 in the report published on June 08th of the current year.
BIIB Trading at 46.63% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.15% of loss for the given period.
Volatility was left at 6.01%, however, over the last 30 days, the volatility rate increased by 17.22%, as shares surge +46.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +47.40% upper at present.
During the last 5 trading sessions, BIIB rose by +51.08%, which changed the moving average for the period of 200-days by +46.63% in comparison to the 20-day moving average, which settled at $294.86. In addition, Biogen Inc. saw 66.19% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BIIB starting from Sandrock Alfred, who sale 7,672 shares at the price of $440.00 back on Jun 07. After this action, Sandrock Alfred now owns 10,169 shares of Biogen Inc., valued at $3,375,680 using the latest closing price.
Guindo Chirfi, the Head of Glob Prod Strat & Com of Biogen Inc., sale 3,087 shares at $440.00 during a trade that took place back on Jun 07, which means that Guindo Chirfi is holding 2,919 shares at $1,358,280 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- +30.76 for the present operating margin
- +81.69 for the gross margin
The net margin for Biogen Inc. stands at +32.38. The total capital return value is set at 19.80, while invested capital returns managed to touch 21.78. Equity return is now at value 27.70, with 12.20 for asset returns.
Based on Biogen Inc. (BIIB), the company’s capital structure generated 73.94 points at debt to equity in total, while total debt to capital is 42.51. Total debt to assets is 32.14, with long-term debt to equity ratio resting at 73.16. Finally, the long-term debt to capital ratio is 42.06.
When we switch over and look at the enterprise to sales, we see a ratio of 3.62, with the company’s debt to enterprise value settled at 0.18. The receivables turnover for the company is 5.15 and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.